Shots:
- Imugene has entered into a co-development collaboration with JW Therapeutics to evaluate Imugene’s oncolytic virus CF33-CD19 (onCARlytics) & JW’s Carteyva for pts with advanced solid tumors
- The company will jointly perform preclinical in vitro & in vivo studies & will advance the combination to a P-I investigator-initiated trial conducted exclusively at CAR-T clinical centers in China
- Collaboration will use Imugene’s CF33-CD19 virus to induce CD19 expression on tumor cells, making them vulnerable to CD19 CAR-T therapy & allowing a “mark-&-kill” strategy
Ref: PR Newswire| Image: JW & Imugene | Press Release
Related News:- VarmX Inks a ~$2.2B Strategic Collaboration and Option Agreement with CSL for VMX-C001 to Advance Coagulation Treatment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
